• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 9

Vehicle-controlled trials for indirect comparison of tacrolimus and pimecrolimus (proportion of patients with moderate to severe disease achieving treatment success at the end of 6 weeks)

TrialDuration (weeks)Mean age (years)Tacrolimus 0.1% (n= 327)Tacrolimus 0.03% (n= 328)Pimecrolimus 1% (n= 129)Vehicle (n= 394)
Paller 200117126.140.7%35.9%N/A6.9%
Kaufmann 200425412.0N/AN/A53.5%10.6%
Hanifin 200116 study #351238.635.4%29.1%N/A7.8%
Hanifin 200116 study #361238.538.2%25.9%N/A5.5%
Pooled rates38.2%30.2%53.5%7.0%
95% CI(32.9%–43.4%)(24.4%–36.0%)(44.9%–62.1%)(4.5%–9.6%)
Heterogeneity statisticsCochrane’s Q0.7 (P=0.72)2.7 (P=0.25)N/A1.5 (P=0.68)
I20%26.9%N/A0%
Tacrolimus 0.03% compared with pimecrolimus: pooled relative risk (95% CI): 0.89 (0.38 to 2.07)
Tacrolimus 0.1% compared with pimecrolimus: pooled relative risk (95% CI): 1.17 (0.43 to 3.20)

From: Results

Cover of Drug Class Review: Topical Calcineurin Inhibitors
Drug Class Review: Topical Calcineurin Inhibitors: Final Report [Internet].
Lee NJ, McDonagh M, Chan B, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.